Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and NK Immunotherapy in Recurrent EGFR-Mutated NSCLC
NCT02845856Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fuda Cancer Hospital. Primary endpoint: Relief degree evaluated by RECIST at 3 months. Started Jul 2016; status: completed.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02845856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02845856.